Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o. (Poland)

Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o. is a Polish pharmaceutical company engaged in development, manufacturing and commercialization of medicinal products and related healthcare categories, with an operating model combining industrial-scale production and in-house research and development. The company focuses on providing modern generic drugs at accessible price points, supported by continuous portfolio development and investments in pharmaceutical analytics and drug-form technology. Manufacturing activities are conducted under Good Manufacturing Practice (GMP) requirements, while products for clinical studies are manufactured in line with GLP and GMP guidelines, supported by laboratory capabilities located at the production site. Business segments include prescription medicines, over-the-counter products, dietary supplements, medical devices and cosmetics, with portfolio coverage across multiple therapeutic areas including urology, psychiatry, pulmonology, allergology, sleep medicine, cardiology, ophthalmology, gastroenterology, endocrinology, pediatrics and rheumatology. The company commercializes products under dedicated brands and product websites spanning melatonin and sleep-related products (Melatonina), magnesium formulations (Magleq / Maglekam), cold/flu products (Zatogrip), iron supplementation (Szelazo), zinc supplementation (Cynek), calming and sleep support (NervoCalm), as well as additional named products such as Katelin and Cyclovena within supplements and health-support ranges. Strategic focus includes expanding R&D capacity through organizational upgrades, specialist hiring and modern analytical/technological equipment investments, as well as participation in externally co-financed innovation projects, including projects supported by the Medical Research Agency and EU/National Recovery and Resilience Plan mechanisms aimed at advancing medical and health sciences solutions. The geographic reach is anchored in Poland with products positioned for EU-quality requirements, supporting broader commercialization potential across European markets through compliant manufacturing and scalable portfolio management.